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1College of Pharmacy, University of Minnesota, Minneapolis, MN; 2School of Public Health, University of Minnesota, Minneapolis, MNA B S T R A C TObjective: To compare the cost-effectiveness of alternate treatment
strategies using second-generation antipsychotics (SGAs) for patients
with schizophrenia. Methods: We developed a Markov model to
estimate the costs and quality-adjusted life-years (QALYs) for differ-
ent sequences of treatments for 40-year-old patients with schizo-
phrenia. We considered ﬁrst-line treatment with one of the four SGAs:
olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone
(ZSD). Patients could switch to another of these antipsychotics as
second-line therapy, and only clozapine (CLZ) was allowed as third-
line treatment. We derived parameter estimates from the Clinical
Antipsychotic Trial of Intervention Effectiveness (CATIE) study and
published sources. Results: The ZSD-QTP strategy (ﬁrst-line treat-
ment with ZSD, change to QTP if ZSD is discontinued, and switch to
CLZ if QTP is discontinued) was most costly while yielding the
greatest QALYs, with an incremental cost-effective ratio (ICER) of
$542,500 per QALY gained compared with the ZSD-RSP strategy.ee front matter Copyright & 2014, International S
r Inc.
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455.However, the ZSD-RSP strategy had an ICER of $5,200/QALY gained
versus the RSP-ZSD strategy and had the greatest probability of being
cost-effective given a willingness-to-pay threshold between $50,000
and $100,000 per QALY. All other treatment strategies were more
costly and less effective than another strategy or combination of other
strategies. Results varied by different time horizons adopted. Con-
clusions: The ZSD-RSP strategy was most cost-effective at a willing-
ness-to-pay threshold between $5,200 and $542,500 per QALY. Our
results should be interpreted with caution because they are based
largely on the CATIE trial with potentially limited generalizability to
all patient populations and doses of SGAs used in practice.
Keywords: CATIE, cost-effectiveness, second-generation antipsychotics,
Markov model, schizophrenia.
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Schizophrenia is a chronic and severely debilitating mental disorder
affecting approximately 1% of the adult US population [1]. Its eco-
nomic burden is substantial because of its attendant long-term care,
numerous comorbidities, and lack of universally effective therapy. In
2002, the estimated total cost of schizophrenia was $62.7 billion, with
$22.7 billion in direct health care costs in the United States [2].
Second-generation antipsychotics (SGAs) were ﬁrst intro-
duced in the 1990s and have been commonly used for the
treatment of schizophrenia being differentiated from conven-
tional antipsychotics in their pharmacological mechanism of
action and few neurologic side effects. The choice of these
medications as either a ﬁrst-line or second-line treatment, how-
ever, has been challenging because each medication has its own
clinical proﬁles of efﬁcacy, safety, and tolerability. Consequently,
different treatment sequences will produce different health and
economic outcomes. For example, a growing body of evidence
suggests that clozapine (CLZ) and olanzapine (OLZ) exhibitsuperior efﬁcacy than do risperidone (RSP), quetiapine (QTP),
and ziprasidone (ZSD), but the former two medications have a
higher propensity for weight gain and glucose abnormalities [3–
5]. Therefore, patients treated with CLZ or OLZ are more likely to
experience more improvement in their general mental state than
do those receiving the other SGAs, but they are also more likely to
experience cardiometabolic events. The American Psychiatric
Association practice guideline (2004) and its guideline watch
(2009) recommend that selection of an antipsychotic be guided
by the patient’s medication history, current symptoms and
comorbid conditions, other concurrent treatments, and the
patient’s preferences [6]. The guideline states that SGAs should
be considered as ﬁrst-line therapy over ﬁrst-generation antipsy-
chotics (FGAs) primarily because of their fewer neurologic side
effects although acknowledges debate over the relative advan-
tages, disadvantages, and cost-effectiveness between FGAs and
SGAs. There has been, however, a lack of speciﬁc recommenda-
tions on which medications should be considered as ﬁrst-line or
second-line interventions among the SGAs.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
alth Policy & Management, 420 Delaware Street SE, MMC 729,
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National Institutes of Mental Health initiated the Clinical Antipsy-
chotic Trial of Intervention Effectiveness (CATIE), a multicentered
trial designed to compare the cost-effectiveness of one FGA (per-
phenazine) with that of four SGAs (OLZ, RSP, QTP, and ZSD) [7,8].
Patients in CATIE were randomly assigned to double-blinded treat-
ment with one of the ﬁve treatments and followed for up to 18
months or until treatment was discontinued because of treatment
inefﬁcacy, intolerable side effects, or patients’ decision. Using data
from CATIE, Rosenheck et al. [8] found that the choice of perphena-
zine as a ﬁrst-line treatment cost less with no difference in quality-
adjusted life-years (QALYs) compared with the four SGAs during the
18-month study period [8]. Because CATIE provided direct compara-
ble data on efﬁcacy, safety, and tolerability of different SGAs from a
representative sample of patients in clinical practice, an additional
study could examine the potential long-term economic and clinical
consequences of using SGAs by using a decision-analytic model.
Previous studies on the cost-effectiveness of antipsychotics
for the treatment of schizophrenia have compared FGA(s) versus
SGA(s) [8–12] or incorporated only single lines of SGA treatments
[13–16]. To our knowledge, only one UK-based study estimated
the long-term outcomes of diabetes on different sequences of
treatments [17]. Accordingly, the objective of our study was to
compare the clinical and cost-effectiveness of different sequen-
ces of SGAs used for patients with schizophrenia from the
perspective of the US health care system.Treatment switch due to treatment inefficacy, intol
Transitions because of treatment-emergent irrever
and coronary heart disease
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Fig. 1 – Schematic overview of Markov model. Individuals with sc
with one of second-generation antipsychotics (SGAs) (olanzapin
different medication in these antipsychotics if they have the rea
refusal to continue. For each SGA, clinical data (e.g., discontinua
reversible and irreversible events) are assumed to be the same
treatment. Only clozapine is allowed to be used as a third-line tr
on clozapine leads to an uncontrolled state in which no antipsyMethods
Model Structure
We developed a Markov model to estimate the costs and QALYs
over a 10-year time horizon of different treatment sequences for a
40-year-old cohort of patients with schizophrenia (Fig. 1). We
considered 12 possible treatment strategies (four possible ﬁrst-
line therapies times three possible second-line therapies). For each
strategy, ﬁrst-line therapy was initiated with one of four SGAs
(OLZ, RSP, QTP, or ZSD). We assumed that all patients would
switch to a second-line treatment among the remaining SGAs if
they discontinued the ﬁrst antipsychotic for any reason (i.e.,
treatment inefﬁcacy, intolerable side effects, their own decision),
as noted in CATIE. Patients who experienced relapse after using
the ﬁrst antipsychotic also discontinued use, which was incorpo-
rated as a discontinuation reason due to treatment inefﬁcacy, and
were switched to second-line treatment. Lacking these reasons,
we assumed that patients would continue their current antipsy-
chotic. Patients who discontinued second-line therapy were
treated with CLZ as a third-line treatment in accordance with
guidance from the Food and Drug Administration [6]. The Food
and Drug Administration limited the use of CLZ to patients who
were nonresponsive to or intolerant of at least two different
antipsychotics before they initiated CLZ because of its rareerable side effects, or patients’ decision 
sible side effects such as metabolic syndrome, diabetes,
1 line treatment 
with irreversible SE
2 line treatment 
with irreversible SE
Clozapine-treatment 
with irreversible SE
Uncontrolled state
with irreversible SE
hizophrenia are assumed to receive their ﬁrst-line treatment
e, risperidone, quetiapine, or ziprasidone) and switch to a
sons such as treatment inefﬁcacy, intolerable SE, or their
tion rates for different reasons, relapse rate, and risk of
whether patients use it as their ﬁrst-line or second-line
eatment after failing two trials of the antipsychotics. Failure
chotic is used. SE, side effect.
Table 1 – Base-case estimates for 18-wk cycles in the Markov model, except where noted otherwise.
Variable Base-case estimate Probability distribution in sensitivity analysis* Reference
Probability of discontinuing treatment because of nonresponse, intolerable side effects, patients’ decision, respectively
Olanzapine 0.092, 0.234, 0.085 Beta (30.36, 299.64), beta (77.22, 252.78), beta (28.05, 301.95) [6]
Risperidone 0.249, 0.168, 0.113 Beta (82.92, 250.08), beta (55.94, 277.06), beta (37.63, 295.37) [6]
Ziprasidone 0.190, 0.449, 0.147 Beta (34.77, 148.23), beta (82.17, 100.83), beta (26.90, 156.10) [6]
Quetiapine 0.249, 0.287, 0.151 Beta (81.92, 247.08), beta (94.42, 234.58), beta (49.68, 279.32) [6]
Clozapine 0.066, 0.374, 0.057 Beta (54.98, 778.02), beta (311.54, 521.46), beta (48.28, 798.72) [21]
Probability of relapse
Olanzapine 0.042 Beta (13.86, 316.14) [6]
Risperidone 0.072 Beta (23.98, 309.02) [6]
Ziprasidone 0.095 Beta (17.39, 165.62) [6]
Quetiapine 0.104 Beta (34.22, 294.78) [6]
Clozapine 0.042 Beta (2.39, 54.61) [21]
Probability of EPS, HPRL,
other events, respectively
Olanzapine 0.018, 0.073, 0.081 Beta (5.94, 324.06), beta (24.09, 305.91), beta (26.73, 303.27) [6]
Risperidone 0.018, 0.079, 0.081 Beta (5.99, 327.01), beta (26.31, 306.69), beta (26.97, 306.03) [6]
Ziprasidone 0.009, 0.060, 0.079 Beta (1.65, 181.35), beta (10.98, 172.02), beta (14.46, 168.54) [6]
Quetiapine 0.009, 0.054, 0.075 Beta (2.96, 326.04), beta (17.77, 311.23), beta (24.68, 304.33) [6]
Clozapine 0.016, 0.040, 0.146 Beta (4.45, 273.55), beta (1.72, 41.28), beta (18.83, 110.17) [21]
Probability of MS
Olanzapine 0.124 Beta (9.18, 64.82) [18]
Risperidone 0.075 Beta (4.05, 49.95) [18]
Ziprasidone 0 Beta (1.00, 36.00)† [18]
Quetiapine 0.061 Beta (4.09, 62.91) [18]
Clozapine 0.151 Beta (1.81, 10.19) [22]
Annual risk of developing
diabetes from MS
0.046 Beta (133.54, 2769.46) [19]
Annual risk of developing
CHD from MS
0.018 Beta (96.21, 5248.79) [20]
CHD, coronary heart disease; EPS, extrapyramidal symptom; HPRL, hyperprolactinemia; MS, metabolic syndrome.
* Beta distributions are speciﬁed by alpha and beta.
† A prior distribution of beta  (1, 5) was assumed to derive a posterior distribution of beta  (1, 36).
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 1 0 – 3 1 9312association with fatal agranulocytosis. Failure on CLZ resulted in
no antipsychotic being used. We assumed that all patients con-
tinue on therapy until they fail third-line therapy. We chose a
cycle length of 18 weeks to recognize any increase in mortality due
to agranulocytosis, which occurs most often within 18 weeks of
initiating CLZ treatment.Clinical Data
Whenever possible, our model parameters were derived using the
results from CATIE, which provided direct comparable evidence
among SGAs. For each SGA, we derived 18-week discontinuation
rates for the base-case analysis from the Kaplan-Meier discontin-
uation-free curves from CATIE [7]. Because the Kaplan-Meier
curves show discontinuation rates separately by different dis-
continuation reasons (i.e., treatment inefﬁcacy, intolerable side
effects, and patient’s decision), we estimated these rates inde-
pendently from each curve. Using the derived 18-week discontin-
uation rates, we then computed the discontinuation-free
probabilities for four time periods (i.e., 18, 36, 54, and 72 weeks)
assuming a constant rate. The derived discontinuation-free
probabilities at each time period were similar to those reported
in the study. The model-speciﬁc sum of all discontinuation rates
also approximated the discontinuation-free (for any reason)
Kaplan-Meier curve from CATIE, with the percentage difference
between them ranging from 0.7% to 13.8%.
Relapse rates for each medication were obtained on the basis
of the proportion of patients hospitalized because of exacerbationof schizophrenia in CATIE [7]. Treatment-emergent side effects
were also deﬁned on the basis of CATIE and included not only
reversible events such as extrapyramidal symptoms (EPSs), hyper-
prolactinemia (HPRL), and any other events (e.g., insomnia, hyper-
somnia, or unpleasant subjective experiences) but also irreversible
events such as metabolic syndrome (MS). More speciﬁcally,
patients were assumed to experience EPSs if their scores on the
Simpson-Angus Extrapyramidal Signs Scale increased 1 or more
after receiving SGA treatment. Such changes in this scale indicate
at least mild severity of extrapyramidal signs [7]. HPRL was
indicated by symptoms such as decreased sex drive, arousal,
ability to reach orgasm, gynecomastia, and galactorrhea (also
menstrual irregularities among female patients). Other events
included any moderate or severe adverse event spontaneously
reported by patients in CATIE. We adopted the deﬁnition of MS
developed by the National Cholesterol Education Program, which
has been most commonly used in prevalence studies [18]. Accord-
ing to the National Cholesterol Education Program, MS is diag-
nosed if three or more risk factors satisfy the deﬁned criteria
among ﬁve risk factors: abdominal obesity, fasting triglycerides,
high-density lipoprotein, blood pressure, and fasting glucose.
Patients who developed MS were at an increased risk of develop-
ing diabetes or coronary heart disease (CHD). We derived the rates
of reversible side effects and MS from CATIE [7,19] and obtained
risks of developing diabetes and CHD from MS using the original
risk modeling studies [20,21]. If patients with irreversible events
(e.g., MS) switched their medication, they were assumed to
experience adverse events relevant to the new medication. They
Table 2 – Component costs of resources used (2013 US $).
Resource category Resource use Unit cost ($) Base-case cost
estimate ($)
Range tested ($) Reference
and data
source
Stable schizophrenia*
Physician visit 1.0 visit/mo 80.93/visit 339.91 169.96–509.87 [23]
Mental health clinic visit 1.5 visit/mo 77.92/visit 490.87 245.43–736.30 [23]
Group intervention 0.5 hr/mo 75.36/hr 158.26 79.13–237.39 [23]
Relapse*,†
Inpatient
Hospitalization day 10.7 d/event 811.57/d 8,683.82 4,341.91–13,025.73 [24]
Emergency room visit 1.0 visit/event 719.09/visit 719.09 359.55–1,078.64 [23]
Day of hospital
treatment
1.25 d/event 750.12/d 937.65 466.82–1,406.47 [23]
Outpatient
Physician visit 1 visit/event 79.37/visit 79.37 39.68–119.05 [23]
Mental health clinic
visit
2 visit/event 76.39/visit 152.79 76.39–229.18 [23]
Home care 2.75 hr/event 95.68/hr 263.11 131.55–394.66 [23]
Group intervention 1.5 hr/event 73.89/hr 110.84 55.42–166.25 [23]
Extrapyramidal symptom†
Benztropinemesylate 4 mg/d 0.41/2 mg 81.70 45.25–101.70 [25,29]
Hyperprolactinemia†
Bromocriptine 5 mg/d 4.90/2.5 mg 961.26 427.85–1,228.53 [26,29]
Type 2 diabetes* 2,695.09 1,347.55–4042.64 [27]
Coronary heart disease* 3,551.79 1,775.90–5,327.69 [28]
Medications
Olanzapine 20.1 mg/d 16.03/7.5 mg 5,413.60 5,311.77–5,431.04 [6,29]
Risperidone 3.9 mg/d 4.19/1 mg
6.97/2 mg
1,827.45‡ 667.64–1,991.62 [6,29]
Quetiapine 543.4 mg/d 12.88/200 mg 4,408.58 4,243.98–4,428.84 [6,29]
Ziprasidone 112.8 mg/d 8.93/40 mg 3,171.56 3,149.50–3,184.91 [6,29]
Clozapine 400 mg/d 1.30/25 mg
3.35/100 mg
2,150.90§ 2,074.79–2,197.59 [6,29]
* The medical care components of the consumer price index for 2013 were assumed to be the same as those for 2012.
† Costs were assumed to be incurred per episode.
‡ An average cost based on equal use of 1-mg and 2-mg tablet was assumed.
§ An average cost based on equal use of 25-mg and 100-mg tablet was assumed.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 1 0 – 3 1 9 313would still be at risk, however, of developing further events (e.g.,
from MS to diabetes) due to the MS related to their ﬁrst medi-
cation. The reversible side effects were assumed to occur within 4
weeks of medication initiation and continue throughout the
remaining period of medication administration [17]. Because
probabilities of discontinuation, relapse, and side effects of CLZ
were not available from CATIE, we derived them from other
studies [22,23]. All baseline estimates are presented in Table 1.
Costs
We adopted the perspective of the US health care system and thus
only direct costs, such as medication and health service use costs,
were considered. Costs for stable schizophrenia and relapse were
estimated by multiplying the number of units of each resource
consumed by the estimated unit cost of each resource and then
summing the products across different resources. Estimates of each
resource use and the unit costs of these resources were obtained
from the literature and administrative data [24,25] (Table 2). Costs of
treating reversible side effects such as EPSs and HPRL involved an
additional medication such as benztropine mesylate and bromoc-
riptine, respectively [26,27]. The annual costs of treating diabetes
and CHD were estimated from the literature and published reports
[28,29]. Costs of SGAs were estimated by multiplying the mean
dosages reported or recommended in CATIE by unit costs obtained
from the average wholesale prices published in the 2013 Drug RedBook [30]. All costs were adjusted to year 2013 dollars using the
medical care component of the consumer price index.
Health Utilities
Relevant health utility values for stable schizophrenia, relapse,
reversible side effects, and diabetes were obtained from a utility
elicitation study [31]. Stable schizophrenia had a utility value of
0.856, and a utility reduction (disutility) value due to relapse, EPSs,
HPRL, and diabetes was 0.358, 0.256, 0.089, and 0.151, respectively,
and applied for one 18-week cycle. Because the Briggs et al. [31]
study did not identify the disutility value for schizophrenia with
CHD, we assumed that this long-term disutility value would be
0.151, which is the same as that for schizophrenia with diabetes
based on the studies in which the disutility for CHD was equal or
almost equal to that of diabetes [32,33]. The disutility due to other
side effects was assumed to be the same as that for HPRL (0.089).
Uncertainty from these assumptions was assessed by sensitivity
analysis. Costs and QALYs were discounted at an annual rate of 3%.
Mortality
The baseline mortality rates for individuals with schizophrenia
were estimated by adjusting the age-speciﬁc all-cause mortality
rates of the general population from US life tables for the relative
increase in suicide rate in patients with schizophrenia. To obtain
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death by suicide in the general population from age-speciﬁc all-
cause mortality in US life tables [34]. The mortality rates due to
suicide in patients with schizophrenia were then added to these
modiﬁed mortality rates, which were used as baseline mortality
rates in our model. The mortality rates by suicide in patients with
schizophrenia were obtained by multiplying the baseline death
rate by suicide in the general population by the standardized
mortality ratio (¼27.94) [35] and did not vary by treatment.
Relative risks for mortality associated with diabetes and CHD
were applied to patients who developed such diseases (2.19; 95%
conﬁdence interval [CI] 1.26–3.79 and 1.67; 95% CI 1.05–2.66 for
diabetes and CHD, respectively) [36,37]. The rate of death from
CLZ-related agranulocytosis was obtained from national registry
data (0.012%; 95% CI 0.005–0.019%) and applied as additive effects
in the model [38]. Finally, higher risk of death with no antipsy-
chotic use compared with any antipsychotic treatment (adjusted
hazard ratio ¼ 1.23; 95% CI 1.19–1.30) was considered for individ-
uals who used no antipsychotic after failing CLZ treatment [39].
Sensitivity Analyses
We conducted one- and two-way sensitivity analyses by varying key
model parameters within their 95% CIs when available, or from 50%
to 150% of their base-case values. Medication costs were varied
using the least and most costly medication among the listed
products with the same active ingredient in the 2013 Drug Red
Book. Cost ranges are shown in Table 2. We also varied the annual
discount rate (0% and 5%) and the age of initiating antipsychotics (30
and 50 years). The probabilities of developing MS for each medi-
cation were additionally varied within their 95% CIs. These CIs were
obtained on the basis of the assumption that the probabilities can be
characterized by beta distributions. Finally, we varied the probabil-
ities of medication discontinuation and relapse after 18 months
from 0 to the base-case estimates because most of the Kaplan-Meier
discontinuation-free curves from CATIE leveled off after 18 months,
indicating that the patients might enter a stable phase.
We conducted probabilistic sensitivity analyses to account for
the uncertainty of each probability of medication discontinua-
tion, relapse, treatment-emergent side effects, and risks of
developing diabetes and CHD from MS (Table 1). A betaTable 3 – Results of the base-case model.*
Treatment sequence
strategy
Total costs
($)
QALYs Increme
Undominated strategies
RSP-ZSD 59,683 7.329
ZSD-RSP 59,737 7.339
ZSD-QTP 65,942 7.351 6
All strategies
RSP-ZSD 59,683 7.329
ZSD-RSP 59,737 7.339
QTP-RSP 62,493 7.311 2
RSP-QTP 63,118 7.310 3
QTP-ZSD 64,846 7.343 5
ZSD-QTP 65,942 7.351 6
OLZ-RSP 72,636 7.275 6
RSP-OLZ 72,788 7.281 6
OLZ-ZSD 74,118 7.299 8
ZSD-OLZ 76,521 7.316 10
OLZ-QTP 77,623 7.285 11
QTP-OLZ 78,345 7.291 12
OLZ, olanzapine; QALYs, quality-adjusted life-years; QTP, quetiapine; RS
* All costs and QALYs are discounted.distribution was assumed for these probability parameters. We
assumed that the mean values were the base-case estimates and
variances were based on the sample size of CATIE or from other
published sources. Estimates of costs and QALYs were obtained
using the values from these probability distributions with 5000
iterations. We plotted the results on a cost-effectiveness accept-
ability curve that demonstrated the probability that each treat-
ment strategy was cost-effective given different willingness-to-
pay values for an additional QALY.
The 10-year time horizon that we used in our base case was
somewhat arbitrary. We chose a 10-year time horizon to capture the
late effects of cardiometabolic events but decided against a lifetime
horizon because of the uncertainty of how long the late effects last.
In a sensitivity analysis, we assumed different time horizons: 18
months (follow-up time of CATIE), 5 years, and 20 years.Results
Base-Case Analysis
Table 3 shows the expected total costs and QALYs for 12 different
treatment strategies over a time horizon of 10 years. In each
strategy, cohorts of 40-year-old patients with schizophrenia
started with one of the four SGAs (OLZ, RSP, QTP, and ZSD),
switched to another antipsychotic among the remaining SGAs if
they discontinued their ﬁrst treatment, and changed to CLZ if
they discontinued their second antipsychotic.
All but three strategies were dominated (i.e., they were more
costly and less effective than another strategy or a combination
of other strategies). The strategy of using RSP ﬁrst, switching to
ZSD if discontinuing RSP, followed by CLZ if discontinuing ZSD,
that is, the RSP-ZSD strategy, had the lowest cost ($59,683) and
lowest effectiveness (7.329 QALYs) among the three undominated
strategies. The ZSD-RSP strategy was slightly more costly
($59,737) and more effective (7.339 QALYs). The comparison of
these two strategies yielded an incremental cost-effective ratio
(ICER) of only $5,200 per QALY gained for the ZSD-RSP strategy
because there was a very small difference in the expected costs
($54) between these two strategies. The ZSD-QTP strategy was the
most costly and most effective ($65,942 and 7.351 QALYs, respec-ntal cost
($)
Incremental
QALYs
Incremental cost per
QALY ($)
– – –
54 0.010 5,197
,205 0.011 542,451
– – –
54 0.010 5,197
,756 0.028 Dominated
,381 0.029 Dominated
,109 0.004 Dominated (extended)
,205 0.011 542,451
,694 0.076 Dominated
,846 0.070 Dominated
,176 0.051 Dominated
,579 0.035 Dominated
,681 0.066 Dominated
,403 0.060 Dominated
P, risperidone; ZSD, ziprasidone.
A.
0 5,000 10,000 15,000 20,000 25,000 30,000
ICER = $5,197/QALY
Cost of diabetes ($1,348, $4,043) Cost saving 27,360
Probability of developing MS – risperidone (0.021, 0.158) Cost saving 27,199
Cost of relapse ($5,473, $16,420) Cost saving 22,077
Probability of developing MS – ziprasidone (0.0007, 0.097) 5,132 18,513
Cost of CHD ($1,776, $5,328) Cost saving 16,877
Cost of risperidone ($668, $1,992) Cost saving 12,822
Discount rate (0%, 5%) 1,060 8,168
Starting age (30 yr, 50 yr) 3,547 7,604
RR for mortality in patients with diabetes (1.26, 3.79) 3,725 6,948
Disutility of CHD (-0.078, -0.026) 4,435      6,276
Cost of HPRL ($428, $1,229) 4,336 5,614
RR for mortality in patients with CHD (1.05, 2.66) 4,722 5,870
Cost of schizophrenia ($495, $1,484) 4,680 5,714
Cost of ziprasidone ($3,150, $3,185) 5,000 5,523
Disutility of other side effects (-0.046, -0.015) 5,031 5,374
Hazard ratio with no antipsychotic use (1.190, 1.299) 5,105   5,367
Cost of clozapine ($2,075, $2,198) 5,167   5,245
Death rate due to agranulocytosis (0.00005, 0.00019) 5,190   5,203
Cost of EPS ($45, $102) 5,190   5,201
Upper bound
Lower bound
B.
0 100,000 200,000 300,000 400,000 500,000 600,000 700,000 800,000 900,000 1,000,000
Probability of developing MS - risperidone (0.021, 0.158) 167,848 Dominated
Probability of developing MS - quetiapine (0.017, 0.129) 338,269 Dominated
Probability of developing MS - clozapine (0.017, 0.391) 355,488 969,508
Cost of risperidone ($668, $1,992) 490,492 909,521
Disutility of CHD (-0.078, -0.026) 505,083 585,790
Disutility of other side effects (-0.046, -0.015) 505,905 584,688
Probability of developing MS – ziprasidone (0.0007, 0.097) 542,097 594,519
Starting age (30 yr, 50 yr) 526,151 576,028
Cost of quetiapine ($4,244, $4,429) 500,565      547,606
RR for mortality in patients with diabetes (1.26, 3.79) 515,205 560,480
Discount rate (0%, 5%) 516,386    560,447
Hazard ratio with no antipsychotic use (1.190, 1.299) 535,185 564,360
Cost of diabetes ($1,348, $4,043) 532,852 552,050
Cost of relapse ($5,473, $16,420) 535,109 549,793
RR for mortality in patients with CHD (1.05, 2.66) 535,407 547,087
Cost of CHD ($1,776, $5,328) 537,424 547,478
Cost of HPRL ($428, $1,229) 539,761 547,820
Death rate due to agranulocytosis (0.00005, 0.00019) 539,438 545,496
Cost of clozapine ($2,075, $2,198) 541,613 541,965
Upper bound
Lower bound
ICER = $542,451/QALY
Fig. 2 – Tornado diagram for univariate sensitivity analyses. (A) The ICER for ziprasidone-risperidone versus risperidone-
ziprasidone. (B) The ICER for ziprasidone-quetiapine versus ziprasidone-risperidone. The parameters were not displayed in
the diagram if the results were more robust than shown here when varying these parameters. CHD, coronary heart disease;
EPS, extrapyramidal symptom; HPRL, hyperprolactinemia; ICER, incremental cost-effectiveness ratio; MS, metabolic
syndrome; QALY, quality-adjusted life-year; RR, relative risk.
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 1 0 – 3 1 9316tively). The ZSD-QTP strategy yielded an incremental cost of
$542,500 per QALY gained relative to the ZSD-RSP strategy.Sensitivity Analyses
The univariate sensitivity analyses comparing ZSD-RSP with RSP-
ZSD and ZSD-QTP with ZSD-RSP are shown in Figure 2. The ICER
comparing ZSD-RSP with RSP-ZSD varied most with changes in
the cost of diabetes, CHD, relapse, and RSP; the probability of MS
for RSP and ZSD; and the discount rate; however, all ICERs
remained less than $30,000 per QALY. When increasing the cost
of diabetes and CHD, ZSD-RSP dominated RSP-ZSD. The same
results were obtained when decreasing the cost of relapse and
RSP and the probability of developing MS for RSP. In comparing
ZSD-QTP with ZSD-RSP, the ICER varied most with changes in the
probability of MS for RSP, QTP, and CLZ and the cost of RSP;
however, all ICERs remained above $165,000 per QALY. When
decreasing the probability of MS for RSP or increasing the
probability of MS for QTP, ZSD-QTP was dominated by ZSD-RSP.
When the probabilities of medication discontinuation and
relapse after 18 months were assumed 0, ZSD-RSP dominated
RSP-ZSD. Compared with ZSD-RSP, ZSD-QTP was more costly
($102,929 vs. $89,296) and produced greater QALYs (7.218 vs.
7.208) with a large ICER value of more than $1,400,000/QALY
gained. Therefore, ZSD-RSP was considered most cost-effective
given a willingness-to-pay threshold of $50,000 or $100,000/QALY
gained when assuming that the patients entered a stable phase
after 18 months.
A probabilistic sensitivity analysis of 5,000 simulations also
showed the ZSD-RSP strategy to be cost-effective compared with
either the RSP-ZSD strategy or the ZSD-QTP strategy given a
willingness-to-pay threshold that is consistent with many well-
accepted medical interventions. Compared with the RSP-ZSD
strategy, the ZSD-RSP strategy was cost-effective in 88.82% of
the simulations given a willingness-to-pay threshold of $50,000
for a QALY gained and 89.80% of the simulations given a thresh-
old of $100,000 per QALY gained. The probabilities that this
strategy was more cost-effective than the ZSD-QTP strategy were
99.96% and 98.82% with a willingness-to-pay threshold of $50,000
and $100,000 per QALY, respectively. The ZSD-RSP strategy as the
most cost-effectiveness option was also suggested by the cost-0%
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Fig. 3 – Cost-effectiveness acceptability curves with three undom
QTP, quetiapine; RSP, risperidone; ZSD, ziprasidone.effectiveness acceptability curve, which was drawn with three
undominated treatment strategies (Fig. 3).
Results varied by time horizon. With a time horizon of 18
months, all other treatment strategies were dominated by four
strategies: RSP-ZSD, OLZ-RSP, OLZ-ZSD, and OLZ-QTP (from the
least to the most costly treatment option). All ICER values,
however, were more than $1,400,000 per QALY gained, indicating
that RSP-ZSD was favored with a willingness-to-pay threshold of
$50,000 and $100,000 per QALY. With a time horizon of 5 years,
the same three treatment strategies (RSP-ZSD, ZSD-RSP, and ZSD-
QTP) dominated all other strategies as the results of base case
with a time horizon of 10 years. On comparing with the results
with a time horizon of 10 years, however, we found that the ICER
of ZSD-RSP increased up to $126,400 per QALY gained versus RSP-
ZSD, suggesting that RSP-ZSD was still favorable given a
willingness-to-pay threshold conventionally accepted. With a
time horizon of 20 years, two treatment strategies (ZSD-RSP
and ZSD-QTP) dominated all other strategies. That is, the RSP-
ZSD strategy was dominated by ZSD-RSP and considered not
being cost-effective any more in this case. The ZSD-QTP strategy
was the most costly and produced the greatest QALY with an
ICER of $138,500 per QALY gained compared with the ZSD-RSP
strategy. Therefore, ZSD-RSP was the most cost-effective treat-
ment option in considering a willingness-to-pay threshold, which
was the same as the base-case results.Discussion
We found the ZSD-RSP strategy to be a cost-effective option for
willingness-to-pay thresholds between $50,000 and $100,000 per
QALY. The incremental cost-effectiveness of this strategy was
estimated to be $5,200 per QALY gained when compared with the
RSP-ZSD strategy. Although the ZSD-QTP strategy yielded the
greatest QALY, it was most costly with an ICER of $542,500 per
QALY gained when compared with the ZSD-RSP strategy.
In sensitivity analyses, the ZSD-QTP strategy was the most
costly, producing the greatest QALY, followed by the ZSD-RSP
strategy and the RSP-ZSD strategy, which was consistent with the
base-case analysis. The ICERs of the ZSD-QTP strategy compared
with those of the ZSD-RSP strategy ranged from $167,800 to0,000 400,000 500,000 600,000 
pay per QALY ($)
RSP-ZSD
ZSD-RSP
ZSD-QTP
inated treatment strategies. QALY, quality-adjusted life-year;
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 1 0 – 3 1 9 317$969,500 per QALY gained, most of which were higher than the
threshold values conventionally reported. All ICERs of the ZSD-
RSP strategy versus the RSP-ZSD strategy, however, were below
$50,000 per QALY gained. The results of favoring the ZSD-RSP
strategy with a conventionally accepted threshold were robust
when assuming that patients entered a stable phase after 18
months. Probabilistic sensitivity analyses also showed that the
ZSD-RSP strategy was a cost-effective option given a willingness-
to-pay value ranging from $5,200 to $286,000. The cardiometa-
bolic risk of each medication was the most signiﬁcant factor
leading our results. Because ZSD possessed little or no risk for MS,
the strategies including this agent were considered to be cost-
effective whereas all the strategies including OLZ with the great-
est metabolic risk were dominated. Among the agents with an
intermediate risk for metabolic disruption, RSP was preferred
over QTP because the rates of discontinuation and relapse were
lower among those assigned to RSP. Consequently, the strategies
with the combination of ZSD and RSP were among the more cost-
effective options. Results, however, varied by different time
horizons adopted. With a time horizon of 18 months or 5 years,
the RSP-ZSD strategy was considered to be cost-effective with an
acceptable threshold. The ZSD-RSP strategy, however, became a
cost-effective option in 20-year follow-up. This suggests that the
favored treatment strategy shifts from RSP-ZSD to ZSD-RSP as the
model adopts a longer time horizon. As the time horizon
increased, patients assigned to ZSD, which had little to no
metabolic risk, received greater beneﬁt compared with those
assigned other ﬁrst-line therapies because of the long-term
beneﬁts of reduced metabolic events. This resulted in ﬁrst-line
treatment with ZSD being cost-effective when adopting a rela-
tively long time horizon.
To our knowledge, this is the ﬁrst analysis to quantitatively
compare different SGA treatment strategies excepting a single
UK-based study [17]. Most of the previous analyses have generally
compared the cost-effectiveness of a single antipsychotic agent
with that of another agent and not considered various treatment
strategies from multiple uses of antipsychotics. Change or dis-
continuation of antipsychotic medications, however, frequently
occurs during the treatment of schizophrenia for reasons such as
inadequate efﬁcacy, unacceptable side effects, or a patient’s
refusal to continue an antipsychotic. The present study consid-
ered switching and discontinuing antipsychotic medications and
examined the potential long-term consequences of various treat-
ment strategies. Although the UK-based study also derived some
of its clinical data from CATIE, there are differences between this
study and that study. First, it assumed that patients would
receive 1 of 12 different treatment options, each consisting of
two of four SGAs (aripiprazole, OLZ, QTP, and RSP) followed by
CLZ. Thus, each treatment strategy was always composed of
three SGAs. In our study, however, patients were allowed to
continue the antipsychotic unless they had reasons to discon-
tinue as noted earlier. This assumption made each treatment
strategy consist of at least one to three SGAs. If patients had no
reason to discontinue their ﬁrst-line SGA treatment, we assumed
that the patients would continue using this antipsychotic agent
for the whole cycle. In this case, monotherapy was the treatment
strategy. The strategy, however, consisted of three SGAs if
patients had reasons to discontinue the ﬁrst-line and second-
line treatment. Second, new-onset metabolic syndrome and
cardiovascular disease among patients treated with SGAs were
also incorporated in our study although only diabetes was
accounted for in the UK study. The association between the use
of SGAs and risks of metabolic syndrome and cardiovascular
disease has been consistently reported [5,40,41]. To consider a
treatment-emergent cardiovascular disease, we ﬁrst derived the
incidence rates of metabolic syndrome from the literature using
the CATIE data [19]. The risks of developing CHD from MS werethen obtained from the Framingham CHD risk model [21]. The
incidence rates of diabetes also differed in two studies. We
obtained the risks of developing diabetes from MS using the
diabetes risk model [20], and the incidence rates of MS were
derived from CATIE. The UK study referred, however, another
epidemiological study to obtain the risks of diabetes. Finally, our
study included ZSD instead of aripiprazole as one of the SGAs
because CATIE had not included aripiprazole, which received its
US licensure approval only after the study had been begun. In the
UK study, however, aripiprazole was selected instead of ZSD on
the basis of the treatment recommendation for the long-term
management of schizophrenia made by the UK National Health
Service [42]. In our study, the ZSD-related data were provided
from CATIE along with data of the other SGAs. Because aripipra-
zole was not included in our study, direct comparisons of our
results with the results of the UK study are not possible. The
ranges of costs and QALYs between the two studies, however,
differed little. Discounted QALYs and costs in the UK study for
different treatment strategies ranged from 6.573 to 6.618 and
£43,835 to £45,645; our results showed these to range from 7.275
to 7.351 and $59,683 to $78,345, respectively.
Among the SGAs addressed in the American Psychiatric
Association guideline (2004), aripiprazole was not included in
this study because of a lack of direct comparative data. Although
some clinical trials compared the efﬁcacy and safety of aripirpa-
zole with another SGA (i.e., OLZ, RSP, or ZSD) as a single-line
treatment, patient population and duration of these studies were
not comparable with CATIE [43–47]. For example, these
aripiprazole-involved studies lasted only for 4 weeks to 52 weeks.
In addition, no study compared the risk of MS for aripiprazole
with other SGAs, making it difﬁcult to derive irreversible events
data for aripiprazole. Although evidence was not sufﬁcient
enough to include it in our model, it is notable that aripiprazole
has been recommended and considered in clinical practice as
other SGAs. Accordingly, its clinical proﬁles are worth assessing
in comparison with those of other SGAs. A recent comprehensive
review study found that the overall efﬁcacy of aripiprazole might
be similar to that of RSP, somewhat better than that of ZSD, and
slightly less superior to that of OLZ [48]. Regarding side effects,
aripiprazole has been known to have less association with weight
gain, heart problems, or prolactin increase than do OLZ and RSP,
although it may cause some extrapyramidal effects. The authors,
however, addressed limited evidence for these ﬁndings and
requirements of more trials and research for aripiprazole. More-
over, several studies compared the cost-effectiveness of aripipra-
zole with that of other SGAs. One study demonstrated favorable
cost-effective outcomes of aripiprazole relative to those of other
SGAs (OLZ, QTP, and RSP) [49], whereas three other studies
favored these SGAs over aripiprazole [14,16,50]. These studies
sponsored by the pharmaceutical manufacturers used different
model assumptions, resulting in conﬂict ﬁndings. Because of the
inconsistency of the results, it is challenging to include aripipra-
zole in interpreting our ﬁndings with other SGAs. Also, time
horizons used in these studies (26 weeks to 1 year) were relatively
short compared with 10 years in our study, indicating that they
may not be long enough to capture the long-term outcomes from
the treatment of schizophrenia as a chronic illness. Future direct
head-to-head long-term comparative data for aripiprazole are
needed to help identify comparative effectiveness of this
medication.
Our study is largely dependent on patient population and the
medication doses used in CATIE. For example, we derived the
probabilities of MS from the CATIE population whose baselines
were at signiﬁcantly greater risk for cardiometabolic events
compared with the general population [51,52]. Subjects in CATIE
having been treated with antipsychotics for 14 years on average
before participating in the study might have increased
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estimating the probabilities of treatment-emergent MS used in
our model, which might also affect the resulting incidence of
diabetes and CHD. Therefore, our analysis might overestimate
the risks of the incidence of MS, diabetes, and CHD in antipsy-
chotics such as OLZ, RSP, and QTP. In particular, OLZ, the most
associated with such conditions, might be most inﬂuenced,
whereas ZSD might not be affected by overestimating such risks
because it is associated with little or no treatment-emergent MS.
In addition, our estimates related to ZSD are less robust because
fewer patients received ZSD in CATIE. To compensate for this
limitation, we tested the effect of reducing the probabilities of MS
by varying these probabilities within their 95% CIs. As noted
previously, the ICERs in the base-case results were sensitive to
changes in these probabilities for RSP, ZSD, QTP, and CLZ. Results
of this test, however, still showed that the ZSD-RSP strategy was
a favorable cost-effective option with the conventionally
accepted willingness-to-pay threshold. Regarding the medication
doses in CATIE, a relatively higher proportion of patients received
the maximal dose of QTP and ZSD compared with those assigned
to other SGAs. Changes in the doses of these medications might
affect the results of our model. As the CATIE group noted,
however, the doses of all medications in the study were generally
similar to the average doses prescribed for patients with schiz-
ophrenia in the United States during its study period [7]. They
argued that they used the dose ranges on the basis of their
knowledge of clinical practice patterns and information from the
manufacturer of each medication. There are several limitations
to this study. First, outcomes of antipsychotics were assessed by
considering a response rate, rates of no or tolerable side effects,
patients’ decision to continue using a medication, and relapse
rate, but not the therapeutic efﬁcacy per se. In other words, the
effectiveness of antipsychotics was evaluated with QALYs and
not with the improvement on measures of symptom severity, for
example, using the Positive and Negative Syndrome Scale or the
Clinical Global Impressions Scale. This is of concern because
treatments differentially improve symptom severity in patients
with schizophrenia. In particular, CATIE results showed that total
Positive and Negative Syndrome Scale scores improved most in
patients treated with OLZ, followed by RSP, QTP, and ZSD.
Improvement in Clinical Global Impressions Scale scores was
greatest in patients treated with OLZ, followed by RSP, ZSD, and
QTP [7]. Therefore, our results might underestimate the beneﬁts
of OLZ and RSP by overlooking their improvement but favor QTP
and ZSD despite their relatively small symptom improvement.
Second, patients who failed two consecutive treatments (among
OLZ, RSP, QTP, and ZSD) followed by CLZ (as a third-line therapy)
were assumed to take no additional antipsychotic given that CLZ
has been the treatment choice for refractory schizophrenia and
there has been no guideline regarding the treatment of CLZ-
refractory patients. Although medication combinations or dose
increases are sometimes used for these patients in clinical
practice, the therapeutic utility of these approaches is yet to be
ﬁrmly determined. One meta-analysis study found no overall
advantages for the addition of a second antipsychotic to CLZ
treatment [53]. Another meta-analysis study showed modest
beneﬁt of augmentation of CLZ with a second antipsychotic for
patients not responding fully to CLZ [54]. Primarily, these combi-
nations take various forms including a wide range of medications
in addition to antipsychotics, making it difﬁcult to determine a
simple treatment regimen for such patients. Therefore, we
assumed that CLZ-refractory patients would take no further
antipsychotics. We do not believe that this assumption had a
signiﬁcant effect on our base-case results because patients spend
only 2.0 to 2.2 years on average in an uncontrolled state, depend-
ing on the treatment strategy. This limitation, however, should
be considered when interpreting our results until clearerguidance becomes available on the treatment of CLZ-refractory
patients. Third, our model considered only direct medical costs
from the perspective of the US health care system. In other
words, indirect costs (e.g., productivity costs and informal
caregiver time) were not included. We assumed that economic
outcomes from different pharmacological treatment strategies
were expected to vary because of different medication costs
and follow-up costs generated from each medication-related side
effects and relapse. Indirect costs were expected not to vary
considerably for using different SGAs; thus, these costs would be
counterbalanced in comparing the ﬁnal outcomes. We acknowl-
edge, however, that indirect costs can be substantial in the
treatment of schizophrenia. If indirect costs were included with
an alternative perspective, the outcomes from this assumption
would represent the burden of patients with schizophrenia more
precisely. In addition, we assumed that patients who had the
discontinuation reasons would continue switching to another
antipsychotic until they receive three different lines of therapy.
In this way, we could evaluate all possible sequential strategies. It
is possible, however, that such patients might entirely stop taking
their ﬁrst-line or second-line therapy and not proceed to the next
treatment for some reason. Finally, we assumed that patients’
responses to a certain SGA were independent of their responses to
other SGAs because each SGA has shown different pharmacology,
kinetics, overall efﬁcacy, tolerability, and response.Conclusions
In conclusion, our analysis suggests that ZSD should be consid-
ered as a ﬁrst-line treatment for patients with schizophrenia. If
patients discontinue ZSD for reasons such as inadequate efﬁcacy,
unacceptable side effects, or their refusal to continue, either QTP
or RSP is recommended as a second-line treatment. Switching to
QTP will produce greater effectiveness but cost much more than
will switching to RSP (7.351 QALYs vs. 7.339 QALYs and $65,942
vs. $59,737, respectively) with an ICER of $542,500/QALY gained.
Changing to RSP with an ICER of $5,200/QALY gained would be a
cost-effective treatment strategy given a conventionally accepted
threshold of ICER. Our results, however, should be interpreted
with caution because they are based largely on CATIE with
potentially limited generalizability in terms of patient popula-
tions and the doses of SGAs used.
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